Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents

References

• Kornberg, R D.; Klug, A. The nucleosome.Sci. Am. 1981, 244, 52–64. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Khorasanizadeh, S. The nucleosome: from genomic organization to genomic regulation.Cell 2004, 116, 259–272. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Litt, M D.; Simpson, M.; Recillas-Targa, F.; Prioleau, M N.; Felsenfeld, G. Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci.EMBO J. 2001, 20, 2224–2235. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Grant, P A. A tale of histone modifications.Genome Biol. 2001, 2, REVIEWS0003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bannister, A J.; Schneider, R.; Kouzarides, T. Histone methylation: dynamic or static?Cell 2002, 109, 801–806. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Strahl, B D.; Allis, C D. The language of covalent histone modifications.Nature 2000, 403, 41–45. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Peters, A H.; Mermoud, J E.; O'Carroll, D.; Pagani, M.; Schweizer, D.; Brockdorff, N.; Jenuwein, T. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin.Nat. Genet. 2002, 30, 77–80. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kondo, Y.; Shen, L.; Issa, J P. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.Mol. Cell. Biol. 2003, 23, 206–215. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Peterson, C L.; Laniel, M A. Histones and histone modifications.Curr. Biol. 2004, 14, R546–R551. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Agalioti, T.; Chen, G.; Thanos, D. Deciphering the transcriptional histone acetylation code for a human gene.Cell 2002, 111, 381–392. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Martens, J H.; Verlaan, M.; Kalkhoven, E.; Zantema, A. Cascade of distinct histone modifications during collagenase gene activation.Mol. Cell. Biol. 2003, 23, 1808–1816. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Roth, S Y.; Denu, J M.; Allis, C D. Histone acetyltransferases.Annu. Rev. Biochem. 2001, 70, 81–120. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Etchegaray, J P.; Lee, C.; Wade, P A.; Reppert, S M. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock.Nature 2003, 421, 177–182. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Marks, P A.; Miller, T.; Richon, V M. Histone deacetylases.Curr. Opin. Pharmacol. 2003, 3, 344–351. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• North, B J.; Verdin, E. Sirtuins: Sir2-related NAD-dependent protein deacetylases.Genome Biol. 2004, 5, 224. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wen, Y D.; Perissi, V.; Staszewski, L M.; Yang, W M.; Krones, A.; Glass, C K.; Rosenfeld, M G.; Seto, E. The histone deacetylase-3 complex contains nuclear receptor corepressors.Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 7202–7207. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Luo, J.; Li, M.; Tang, Y.; Laszkowska, M.; Roeder, R G.; Gu, W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo.Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 2259–2264. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Johnstone, R W.; Licht, J D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?Cancer Cell 2003, 4, 13–18. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gore, S D.; Carducci, M A. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.Expert Opin. Investig. Drugs 2000, 9, 2923–2934. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Carducci, M A.; Gilbert, J.; Bowling, M K.; Noe, D.; Eisenberger, M A.;Sinibaldi, V.; Zabelina, Y.; Chen, T L.; Grochow, L B.; Donehower, R C. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.Clin. Cancer Res. 2001, 7, 3047–3055. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gilbert, J.; Baker, S D.; Bowling, M K.; Grochow, L.; Figg, W D.; Zabelina, Y.; Donehower, R C.; Carducci, M A. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.Clin. Cancer Res. 2001, 7, 2292–2300. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gore, S D.; Weng, L J.; Zhai, S.; Figg, W D.; Donehower, R C.; Dover, G J.; Grever, M.; Griffin, C A.; Grochow, L B.; Rowinsky, E K.; Zabalena, Y.; Hawkins, A L.; Burks, K.; Miller, C B. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.Clin. Cancer Res. 2001, 7, 2330–2339. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gore, S D.; Weng, L J.; Figg, W D.; Donehower, R C.; Dover, G.; Grever, M R.; Griffin, C.; Grochow, L B.; Hawkins, A.; Burks, K.; Zabelena, Y.; Miller, C B. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.Clin. Cancer Res. 2002, 8, 963–970. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.Cancer Res. 2002, 62, 4916–4921. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Aron, J L.; Parthun, M R.; Marcucci, G.; Kitada, S.; Mone, A P.; Davis, M E.; Shen, T.; Murphy, T.; Wickham, J.; Kanakry, C.; Lucas, D M.; Reed, J C.; Grever, M R.; Byrd, J C. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.Blood 2003, 102, 652–658. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Byrd, J C.; Shinn, C.; Ravi, R.; Willis, C R.; Waselenko, J K.; Flinn, I W.; Dawson, N A.; Grever, M R. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.Blood 1999, 94, 1401–1408. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Xiao, J J.; Foraker, A B.; Swaan, P W.; Liu, S.; Huang, Y.; Dai, Z.; Chen, J.; Sadee, W.; Byrd, J.; Marcucci, G.; Chan, K K. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.J. Pharmacol. Exp. Ther. 2005, 313, 268–276. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sandor, V.; Bakke, S.; Robey, R W.; Kang, M H.; Blagosklonny, M V.; Bender, J.; Brooks, R.; Piekarz, R L.; Tucker, E.; Figg, W D.; Chan, K K.; Goldspiel, B.; Fojo, A T.; Balcerzak, S P.; Bates, S E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Clin. Cancer Res. 2002, 8, 718–728. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Piekarz, R L.; Robey, R.; Sandor, V.; Bakke, S.; Wilson, W H.; Dahmoush, L.; Kingma, D M.; Turner, M L.; Altemus, R.; Bates, S E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.Blood 2001, 98, 2865–2868. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Marshall, J L.; Rizvi, N.; Kauh, J.; Dahut, W.; Figuera, M.; Kang, M H.; Figg, W D.; Wainer, I.; Chaissang, C.; Li, M Z.; Hawkins, M J. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.J. Exp. Ther. Oncol. 2002, 2, 325–332. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Byrd, J C.; Marcucci, G.; Parthun, M R.; Xiao, J J.; Klisovic, R B.; Moran, M.; Lin, T S.; Liu, S.; Sklenar, A R.; Davis, M E.; Lucas, D M.; Fischer, B.; Shank, R.; Tejaswi, S L.; Binkley, P.; Wright, J.; Chan, K K.; Grever, M R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.Blood 2005, 105, 959–967. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Berg, S L.; Stone, J.; Xiao, J J.; Chan, K K.; Nuchtern, J.; Dauser, R.; McGuffey, L.; Thompson, P.; Blaney, S M. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.Cancer Chemother. Pharmacol. 2004, 54:85–88. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Klisovic, D D.; Katz, S E.; Effron, D.; Klisovic, M I.; Wickham, J.; Parthun, M R.; Guimond, M.; Marcucci, G. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.Investig. Ophthalmol. Vis. Sci. 2003, 44, 2390–2398. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• He, L Z.; Tolentino, T.; Grayson, P.; Zhong, S.; Warrell, R P., Jr.; Rifkind, R A.; Marks, P A.; Richon, V M.; Pandolfi, P P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.J. Clin. Invest. 2001, 108, 1321–1330. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Munster, P N.; Troso-Sandoval, T.; Rosen, N.; Rifkind, R.; Marks, P A.; Richon, V M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast Cancer Cells.Cancer Res. 2001, 61, 8492–8497. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kelly, W K.; Richon, V M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J H.; Rifkind, R.; Marks, P A.; Scher, H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.Clin. Cancer Res. 2003, 9, 3578–3588. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Duvic, M.; Talpur, R.; Chiao, N.; Chiao, J. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).Blood 2003, 102, 179a. [CSA]
   Web of Science ®Google Scholar
• Garcia-Manero, G.; Issa, J.; Cortes, J.; Koller, C.; O'Brien, S.; Estey, E.; Canalli, A.; Chiao, J.; Richon, V M.; Kantarjian, H. Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients with advanced leukemia or myelodisplastic syndromes.Proc. ASCO 2004, 23. [CSA]
   Google Scholar
• Perucca, E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.CNS Drugs 2002, 16, 695–714. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sztajnkrycer, M D. Valproic acid toxicity: overview and management.J. Toxicol., Clin. Toxicol. 2002, 40, 789–801. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Njolstad, P R.; Skjeldal, O H.; Agsteribbe, E.; , et al. Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity.Pediatr. Neurol. 1997, 16, 160–162. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Raza, M.; Al-Bekairi, A M.; Ageel, A M.; Qureshi, S. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury.Pharmacol. Res. 1997, 35, 153–157. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dreifuss, F E.; Santilli, N.; Langer, D H.; Sweeney, K P.; Moline, K A.; Menander, K B. Valproic acid hepatic fatalities: a retrospective review.Neurology 1987, 37, 379–385. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Driever, P H.; Knupfer, M M.; Cinatl, J.; Wolff, J E. Valproic acid for the treatment of pediatric malignant glioma.Klin. Padiatr. 1999, 211, 323–328. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cinatl, J., Jr.; Kotchetkov, R.; Blaheta, R.; Driever, P H.; Vogel, J U.; Cinatl, J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.Int. J. Oncol. 2002, 20, 97–106. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kawagoe, R.; Kawagoe, H.; Sano, K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways.Leuk. Res. 2002, 26, 495–502. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Phiel, C J.; Zhang, F.; Huang, E Y.; Guenther, M G.; Lazar, M A.; Klein, P S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.J. Biol. Chem. 2001, 276, 36734–36741. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gottlicher, M.; Minucci, S.; Zhu, P.; Kramer, O H.; Schimpf, A.; Giavara, S.; Sleeman, J P.; Lo Coco, F.; Nervi, C.; Pelicci, P G.; Heinzel, T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.EMBO J. 2001, 20, 6969–6978. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kuendgen, A.; Strupp, C.; Aivado, M.; Bernhardt, A.; Hildebrandt, B.; Haas, R.; Germing, U.; Gattermann, N. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.Blood 2004, 104, 1266–1269. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yang, H.; Hoshino, K.; Sanchez-Gonzalez, B.; Kantarjian, H.; Garcia-Manero, G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproiac acid.Leuk. Res. In press., , [CSA]
   Web of Science ®Google Scholar
• Garcia-Manero, G.; Kantarjian, H.; Sanchez-Gonzalez, B.; Faderl, S.; Verstovsek, S.; Ravandi, F.; Rytting, M.; Cortes, J.; Wierda, W.; Hoshino, K.; Yang, H.; Santos-Malave, C.; Fiorentino, J.; Jabbour, E.; Rosner, G.; Issa, J P. Results of a phase I/II study of the combination of 5-aza-2′-deoxycytidine and valproiac acid in patients with leukemia.Blood 2004, 104, 78a. [CSA]
   Web of Science ®Google Scholar
• Jaboin, J.; Wild, J.; Hamidi, H.; Khanna, C.; Kim, C J.; Robey, R.; Bates, S E.; Thiele, C J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.Cancer Res. 2002, 62, 6108–6115. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rosato, R R.; Almenara, J A.; Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.Cancer Res. 2003, 63, 3637–3645. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Plumb, J A.; Finn, P W.; Williams, R J.; Bandara, M J.; Romero, M R.; Watkins, C J.; La Thangue, N B.; Brown, R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.Mol. Cancer Ther. 2003, 2, 721–728. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fournel, M.; Trachy-Bourget, M C.; Yan, P T.; Kalita, A.; Bonfils, C.; Beaulieu, C.; Frechette, S.; Leit, S.; Abou-Khalil, E.; Woo, S H.; Delorme, D.; MacLeod, A R.; Besterman, J M.; Li, Z. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.Cancer Res. 2002, 62, 4325–4330. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jones, P A.; Baylin, S B. The fundamental role of epigenetic events in cancer.Nat. Rev., Genet. 2002, 3, 415–428. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Robertson, K D.; Wolffe, A P. DNA methylation in health and disease.Nat. Rev., Genet. 2000, 1, 11–19. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hennessy, B T.; Garcia-Manero, G.; Kantarjian, H M.; Giles, F J. DNA methylation in haematological malignancies: the role of decitabine.Expert Opin. Investig. Drugs 2003, 12, 1985–1993. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Silverman, L R.; Demakos, E P.; Peterson, B L.; Kornblith, A B.; Holland, J C.; Odchimar-Reissig, R.; Stone, R M.; Nelson, D.; Powell, B L.; DeCastro, C M.; Ellerton, J.; Larson, R A.; Schiffer, C A.; Holland, J F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.J. Clin. Oncol. 2002, 20, 2429–2440. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kornblith, A B.; Herndon, J E., II; Silverman, L R.; Demakos, E P.; Odchimar-Reissig, R.; Holland, J F.; Powell, B L.; DeCastro, C.; Ellerton, J.; Larson, R A.; Schiffer, C A.; Holland, J C. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.J. Clin. Oncol. 2002, 20, 2441–2452. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Issa, J P.; Garcia-Manero, G.; Giles, F J.; Mannari, R.; Thomas, D.; Faderl, S.; Bayar, E.; Lyons, J.; Rosenfeld, C S.; Cortes, J.; Kantarjian, H M. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (Decitabine) in hematopoietic malignancies.Blood 2004, 103, 1635–1640. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bachman, K E.; Park, B H.; Rhee, I.; Rajagopalan, H.; Herman, J G.; Baylin, S B.; Kinzler, K W.; Vogelstein, B. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene.Cancer Cell 2003, 3, 89–95. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nguyen, C T.; Weisenberger, D J.; Velicescu, M.; Gonzales, F A.; Lin, J C.; Liang, G.; Jones, P A. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine.Cancer Res. 2002, 62, 6456–6461. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fahrner, J A.; Eguchi, S.; Herman, J G.; Baylin, S B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.Cancer Res. 2002, 62, 7213–7218. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yang, X.; Phillips, D L.; Ferguson, A T.; Nelson, W G.; Herman, J G.; Davidson, N E. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.Cancer Res. 2001, 61, 7025–7029. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kim, M S.; Blake, M.; Baek, J H.; Kohlhagen, G.; Pommier, Y.; Carrier, F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.Cancer Res. 2003, 63, 7291–7300. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Marchion, D C.; Bicaku, E.; Daud, A I.; Richon, V.; Sullivan, D M.; Munster, P N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.J. Cell. Biochem. 2004, 92, 223–237. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bali, P.; George, P.; Cohen, P.; Tao, J.; Guo, F.; Sigua, C.; Vishvanath, A.; Scuto, A.; Annavarapu, S.; Fiskus, W.; Moscinski, L.; Atadja, P.; Bhalla, K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.Clin. Cancer Res. 2004, 10, 4991–4997. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nimmanapalli, R.; Fuino, L.; Bali, P.; Gasparetto, M.; Glozak, M.; Tao, J.; Moscinski, L.; Smith, C.; Wu, J.; Jove, R.; Atadja, P.; Bhalla, K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.Cancer Res. 2003, 63, 5126–5135. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nimmanapalli, R.; Fuino, L.; Stobaugh, C.; Richon, V.; Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.Blood 2003, 101, 3236–3239. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar